|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,340 KRW | +0.79% |
|
+0.63% | -35.96% |
| 07-04 | Genexine, Inc. Appoints Jaehyun Choi as Head of R&D | CI |
| 07-01 | Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. | CI |
Genexine, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 12.36 million compared to KRW 7 million a year ago. Net loss was KRW 11,565.6 million compared to KRW 23,913.79 million a year ago.
Basic loss per share from continuing operations was KRW 279 compared to KRW 626 a year ago. Basic loss per share was KRW 279 compared to KRW 626 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -35.96% | 191M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +18.20% | 25.98B | |
| -24.33% | 19.27B | |
| -18.26% | 15.99B | |
| -17.95% | 15.66B | |
| -48.32% | 14.5B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
GENEXINE, INC. 
